Skip to main content

Advertisement

Log in

Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

This study was aimed to evaluate the long-term effects of telbivudine (LdT) in the treatment of chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) and to observe the changes of immunological responses during LdT treatment. Clinical data of 80 CHB and 28 HBV-related LC patients who were administered with LdT for 108 weeks and followed up were retrospectively analyzed. The liver function indicators including ALT, AST and γ-GT, HBV DNA copy number in serum and the rates of hepatitis B e antigen (HBeAg) seroconversion were analyzed before and 12, 24, 36, 48, 60, 72, 84, 96 and 108 weeks after LdT treatment in CHB and LC groups. Four serum fibrosis-related markers, including hyaluronic acid (HA), human laminin (LN), human type IV collagen (IV-C) and human N-terminal procollagen III peptide (PC-III), were detected before and after LdT treatment in LC group. The results showed favorable viral suppression and biochemical responses after treatment with LdT for 12 weeks, and a high rate of virological and biochemical control was maintained during the course of 108-week treatment in both CHB and LC groups. The four fibrosis-related markers, especially HA and LN, were down-regulated to some degrees in LC group. Moreover, LdT treatment led to the fluctuation of the circulating interferon-γ (IFN-γ) and interleukin-10 (IL-10) levels at different time points in CHB group. It was concluded that LdT could favorably lead to the virological suppression and biochemical remission. Besides, IFN-γ and IL-10 may represent a suitable and effective predictor of responsiveness during LdT therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 2004,11(2):97–107

    Article  CAS  PubMed  Google Scholar 

  2. Luo Z, Xie Y, Deng M, et al. Prevalence of hepatitis B in the southeast of China: a population-based study with a large sample size. Eur J Gastroenterol Hepatol, 2011,23(8):695–700

    Article  PubMed  Google Scholar 

  3. Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol, 2011,21(6):401–416

    Article  PubMed Central  PubMed  Google Scholar 

  4. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis, 2005,25(Suppl 1):3–8

    Article  PubMed  Google Scholar 

  5. Zhu XF, Lu LX, Wang Y, et al. Effect and predictive elements for 52 weeks’ telbivudine treatment on naive HBeAg positive chronic hepatitis B. Hepat Mon, 2011,11(12):980–985

    Article  PubMed Central  PubMed  Google Scholar 

  6. Pollicino T, Bellinghieri L, Restuccia A, et al. Hepatitis B virus (HBV) induces the expression of interleukin-8 that in turn reduces HBV sensitivity to interferon-alpha. Virology. 2013,444(1–2):317–328

    Article  CAS  PubMed  Google Scholar 

  7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001,34(6):1225–1241

    Article  CAS  PubMed  Google Scholar 

  8. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis, 2002,2(1):43–50

    Article  CAS  PubMed  Google Scholar 

  9. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis, 2002,2(7):395–403

    Article  PubMed  Google Scholar 

  10. Kondo Y, Asabe S, Kobayashi K, et al. Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol, 2004,4(3):425–433

    Article  Google Scholar 

  11. Feng H, Zhang J, Li X, et al. HBX-mediated migration of HBV-replicating HepG2 cells: insights on development of hepatocellular carcinoma. J Biomed Biotechnol, 2009, 2009: 930268

    PubMed Central  PubMed  Google Scholar 

  12. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int, 2011,31(5):676–684

    Article  CAS  PubMed  Google Scholar 

  13. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007,20;357(25):2576–2588

    Article  CAS  PubMed  Google Scholar 

  14. Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther, 2009,14(1):13–22

    CAS  PubMed  Google Scholar 

  15. Phillips MG, Preedy VR, Hughes RD. Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy? Eur J Gastroenterol Hepatol, 2003,15(9):941–944

    Article  PubMed  Google Scholar 

  16. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology, 2000,32(3):477–481

    Article  CAS  PubMed  Google Scholar 

  17. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet, 1986,1(8480):523–525

    Article  CAS  PubMed  Google Scholar 

  18. Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques—a review. Gastrointest Endosc, 1982,28(2):102–104

    Article  CAS  PubMed  Google Scholar 

  19. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol, 1986,2(2):165–173

    Article  CAS  PubMed  Google Scholar 

  20. Cadranel JF, Mathurin P. Prothrombin index decrease: a useful and reliable marker of extensive fibrosis? Eur J Gastroenterol Hepatol, 2002,14(10):1057–1059

    Article  CAS  PubMed  Google Scholar 

  21. Croquet V, Vuillemin E, Ternisien C, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol, 2002,14(10):1133–1141

    Article  CAS  PubMed  Google Scholar 

  22. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology, 1997,113(5):1609–1616

    Article  CAS  PubMed  Google Scholar 

  23. Plevris JN, Haydon GH, Simpson KJ, et al. Serum hyaluronan—a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol, 2000,12(10):1121–1127

    Article  CAS  PubMed  Google Scholar 

  24. Guechot J, Poupon RE, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol, 1994,20(3):388–393

    Article  CAS  PubMed  Google Scholar 

  25. Rauch I, Muller M, Decker T. The regulation of inflammation by interferons and their STATs. JAKSTAT, 2013,2(1):e23820

    PubMed Central  PubMed  Google Scholar 

  26. Bonorino P, Ramzan M, Camous X, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol, 2009,51(3):458–467

    Article  CAS  PubMed  Google Scholar 

  27. Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med, 2007,204(3):667–680

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology, 2009,137(3):1151–1160, 60 e1-e7

    Article  CAS  PubMed  Google Scholar 

  29. Zhang Z, Zhang S, Zou Z, et al. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology, 2011,53(1):73–85

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Jiang Y, Ma Z, Xin G, et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm, 2010,2010: 143026

    PubMed Central  PubMed  Google Scholar 

  31. Gaeta GB, Stornaiuolo G. Therapy of chronic hepatitis B: focus on telbivudine. Dig Liver Dis, 2007,39(Suppl 3):S372–S378

    Article  CAS  PubMed  Google Scholar 

  32. Das A, Maini MK. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis, 2010,28(1):126–132

    Article  PubMed  Google Scholar 

  33. Zheng Y, Huang Z, Chen X, et al. Effects of telbivudine treatment on the circulating CD4(+) T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm, 2012,2012:789859

    Article  PubMed Central  PubMed  Google Scholar 

  34. Shi TD, Zhang JM, Wang XF, et al. Effects of antiviral therapy with telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. Clin Exp Med, 2012,12(2):105–113

    Article  CAS  PubMed  Google Scholar 

  35. Zhao J, Li Y, Jin L, et al. Natural killer cells are characterized by the concomitantly increased interferon-gamma and cytotoxicity in acute resolved hepatitis B patients. PLoS One, 2012,7(11):e49135

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Alatrakchi N, Koziel M. Regulatory T cells and viral liver disease. J Viral Hepat, 2009,16(4):223–229

    Article  PubMed  Google Scholar 

  37. Cottrez F, Groux H. Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation, 2004,77(1 Suppl):S12–S15

    Article  PubMed  Google Scholar 

  38. Stoop JN, van der Molen RG, Baan CC, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology, 2005,41(4):771–778

    Article  CAS  PubMed  Google Scholar 

  39. Nan XP, Zhang Y, Yu HT, et al. Inhibition of viral replication downregulates CD4(+)CD25(high) regulatory T cells and programmed death-ligand 1 in chronic hepatitis B. Viral Immunol, 2012,25(1):21–8

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wang-xian Tang  (唐望先).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meng, N., Gao, X., Yan, W. et al. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 230–234 (2015). https://doi.org/10.1007/s11596-015-1416-3

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-015-1416-3

Key words

Navigation